NCT04811469View on ClinicalTrials.gov

Safety, Tolerability and Pharmacokinetics of CBP-174 in Healthy Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

74

Participants

Timeline

Start Date

May 24, 2021

Primary Completion Date

May 14, 2022

Study Completion Date

May 21, 2022

Conditions
Healthy Adult Subjects
Interventions
DRUG

CBP-174

CBP-174 oral solution, given once

DRUG

Placebo

Placebo oral solution, given once

Trial Locations (1)

3004

Nucleus Network Pty Ltd, Melbourne

All Listed Sponsors
lead

Connect Biopharma Australia Pty Ltd

INDUSTRY